Google
Trusted Resources: News & Events
Latest announcements and gatherings
Public Meeting on Patient-Focused Drug Development for Chronic Pain
Meeting Information:
On July 9, 2018, FDA is hosting a public meeting on Patient-Focused Drug Development for Chronic Pain. FDA is interested in hearing patients’ perspectives on chronic pain, views on treatment approaches, and challenges or barriers to accessing treatments for chronic pain. FDA is particularly interested in hearing from patients who experience chronic pain.
Date: July 9, 2018
Time: 10:00 a.m. – 4:00 p.m. (registration will begin at 9:00am)
Location:
FDA White Oak Campus
10903 New Hampshire Ave.
Building 31, Room 1503 B & C (Great Room)
Silver Spring, MD 20993
This event has ended.
+myBinderRelated Content
-
FDA Clears Graphite Bio to Begin Trial for Gene Therapy in Sickle Cell DiseaseIn response to Graphite Bio’s investig...
-
FDA Awards UNC Researcher $2M Grant to Study Kidney Disease in Sickle Cell AnemiaThe U.S. Food and Drug Administration (F...
-
Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Effi...Background: Hydroxyurea prevents disea...
-
10th DC Community Health Connect Event by Rodham InstituteThis event has ended. Stay tuned for upc...
-
Adverse effect of hydroxyurea on spermatogenesis in patients with sickle cell anemia after 6 months of treatmentThe prognosis of sickle cell anemia (SCA...
-
Annual management of Sickle cell disease conference 2018The Sickle Cell Disease Associat...
-
Bluebird bio acquires Durham, NC, manufacturing site for lentiviral vector productionbluebird bio said today it has acquired ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.